ExploreWatchlistsPricing
  1. JP-listed companies
  2. Astellas Pharma Inc.
  3. Financials
  4. Operating expenses

Astellas Pharma Inc. (4503)

Market cap
¥4.72T
P/E ratio
18.7x
Astellas Pharma develops, manufactures, and sells pharmaceutical products globally through a network of 77 subsidiaries across the US, Europe, and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating expenses (Million JPY)YoY (%)
Mar 31, 2025843,032+13.91%
Mar 31, 2024740,110+17.43%
Mar 31, 2023630,272+14.84%
Mar 31, 2022548,840+8.83%
Mar 31, 2021504,316+1.01%
Mar 31, 2020499,295+1.84%
Mar 31, 2019490,263+16.34%
Mar 31, 2018421,413+15.11%
Mar 31, 2017366,108-2.88%
Mar 31, 2016376,967+19.36%
Mar 31, 2015315,834

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat